Novel strategies for preventing diabetes and obesity complications with natural polyphenols

Current Medicinal Chemistry

Volumn 22, Issue 1, 2015, Pages 150-164

  Carpene C ^a,b   Gomez Zorita, S ^b   Deleruyelle, S ^a,b   Carpene M A ^b  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Adipogenesis; Adipokines; Energy balance; Glucose transport; Insulin resistance

Indexed keywords

ADIPOCYTOKINE; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; CAFFEIC ACID; CHLOROGENIC ACID; CURCUMIN; DAIDZEIN; DEOXYGLUCOSE; FLAVONOL; GALLIC ACID; GENISTEIN; GLUCOSE; GLUCOSE TRANSPORTER 4; HEXOSE; INSULIN; KAEMPFEROL; PHLORIZIN; PICEATANNOL; PLANT EXTRACT; POLYPHENOL; PTEROSTILBENE; QUERCETIN; RESVERATROL; STILBENE DERIVATIVE;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; CELL DIFFERENTIATION; CHEMICAL STRUCTURE; CLINICAL STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG METABOLISM; ENERGY EXPENDITURE; FACILITATION; GLUCOSE TRANSPORT; HUMAN; IN VITRO STUDY; INSULIN SENSITIVITY; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; MUSCLE FUNCTION; NONHUMAN; OBESITY; OXIDATIVE PHOSPHORYLATION; PROADIPOCYTE; ANIMAL; CHEMISTRY; DRUG EFFECTS; INSULIN RESISTANCE; METABOLISM;

ADIPOCYTES; ANIMALS; DIABETES MELLITUS; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; OBESITY; POLYPHENOLS; STILBENES;

EID: 84929082341     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140815124052     Document Type: Article

References (120)

1. Bastard, J. P.; Fève, B. Physiology and Physiopathology of adipose tissue. 1st ed. Springer-Verlag: Paris, 2013.
2. Duncan, B. B.; Schmidt, M. I.; Pankow, J. S.; Ballantyne, C. M.; Couper, D.; Vigo, A.; Hoogeveen, R.; Folsom, A. R.; Heiss, G. Atherosclerosis Risk in Communities Study. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes, 2003, 52, 1799-1805.
3. Minokoshi, Y.; Kahn, C. R.; Kahn, B. B. Tissue-specific ablation of the GLUT4 glucose transporter or the insulin receptor challenges assumptions about insulin action and glucose homeostasis. J. Biol. Chem., 2003, 278, 33609-33612.
4. DeFronzo, R. A. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes, 2009, 58, 773-795.
5. Borriello, A.; Cucciolla, V.; Della Ragione, F.; Galletti, P. Dietary polyphenols: focus on resveratrol, a promising agent in the prevention of cardiovascular diseases and control of glucose homeostasis. Nutr. Metab. Cardiovasc. Dis., 2010, 20, 618-625.
6. Park, T.; Kim, Y. Phytochemicals as potential agents for prevention and treatment of obesity and metabolic diseases. Anti-Obes. Drug Discov. Develop., 2011, 1, 150-185.
7. Schrauwen, P.; Timmers, S. Can resveratrol help to maintain metabolic health? Proc. Nutr. Soc., 2014, 73, 271-277.
8. Xiao, J.; Hogger, P. Influence of diabetes on the pharmacokinetic behavior of natural polyphenols. Curr. Drug Metab., 2014, 15, 23-29.
9. Su, H. C.; Hung, L. M.; Chen, J. K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab., 2006, 290, E1339-E1346.
10. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discovery, 2006, 5, 493-506.
11. Maraculla, M. T.; Alberdi, G.; Gomez, S.; Tueros, I.; Bald, C.; Rodriguez, V. M.; Martinez, J. A.; Portillo, M. P. Effects of different doses of resveratrol on body fat and serum parameters in rats fed a hypercaloric diet. J. Physiol. Biochem., 2009, 65, 369-376.
12. Kim, S.; Jin, Y.; Choi, Y.; Park, T. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem. Pharmacol., 2011, 81, 1343-1351.
13. Szkudelska, K.; Szkudelski, T. Resveratrol, obesity and diabetes. Eur. J. Pharmacol., 2010, 635, 1-8.
14. Zamora-Ros, R.; Andres-Lacueva, C.; Lamuela-Raventós, R. M.; Berenguer, T.; Jakszyn, P.; Martínez, C.; Sánchez, M. J.; Navarro, C.; Chirlaque, M. D.; Tormo, M. J.; Quirós, J. R.; Amiano, P.; Dorronsoro, M.; Larrañaga, N.; Barricarte, A.; Ardanazn, E.; González, C. A. Concentrations of resveratrol and derivatives in foods and estimation of dietary intake in a Spanish population: European Prospective Investigation into Cancer and Nutrition (EPIC)-Spain cohort. Br. J. Nutr., 2008, 100, 188-196.
15. Xiao, J.; Ni, X.; Kai, G.; Chen, X. A review on structure-activity relationship of dietary polyphenols inhibiting α-amylase. Crit. Rev. Food Sci. Nutr., 2013, 53, 497-506.
16. Xiao, J.; Kai, G.; Yamamoto, K.; Chen, X. Advance in dietary polyphenols as α-glucosidases inhibitors: a review on structureactivity relationship aspect. Crit. Rev. Food Sci. Nutr., 2013, 53, 818-836.
17. Meydani, M.; Hasan, S. T. Dietary polyphenols and obesity. Nutrients, 2010 2, 737-751.
18. Rothwell, J. A.; Urpi-Sarda, M.; Boto-Ordoñez, M.; Knox, C.; Llorach, R.; Eisner, R.; Cruz, J.; Neveu, V.; Wishart, D.; Manach, C.; Andres-Lacueva, C.; Scalbert, A. Phenol-Explorer 2.0: a major update of the Phenol-Explorer database integrating data on polyphenol metabolism and pharmacokinetics in humans and experimental animals. Database (Oxford), 2012, 2012, bas031.
19. Brasnyó, P.; Molnár, G. A.; Mohás, M.; Markó, L.; Laczy, B.; Cseh, J.; Mikolás, E.; Szijártó, I. A.; Mérei, A.; Halmai, R.; Mészáros, L. G.; Sümegi, B.; Wittmann, I. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr., 2011, 106, 383-389.
20. Crandall, J. P.; Oram, V.; Trandafirescu, G.; Reid, M.; Kishore, P.; Hawkins, M.; Cohen, H. W.; Barzilai, N. Pilot study of resveratrol in older adults with impaired glucose tolerance. J. Gerontol. A Biol. Sci. Med. Sci., 2012, 67, 1307-1312.
21. Timmers, S.; Konings, E.; Bilet, L.; Houtkooper, R. H.; Van De Weijer, T.; Goossens, G.; Hoeks, J.; Van Der Krieken, S.; Ryu, D.; Kersten, S.; Moonen-Kornips, E.; Hesselink, M.; Kunz, I.; Schrauwen-Hinderling, V.; Blaak, E.; Auwerx, J.; Schrauwen, P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab., 2011, 14, 612-622.
22. Baur, J. A.; Pearson, K. J.; Price, N. L.; Jamieson, H. A.; Lerin, C.; Kalra, A.; Prabhu, V. V.; Allard, J. S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P. J.; Poosala, S.; Becker, K. G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K. W.; Spencer, R. G.; Lakatta, E. G.; Le Couteur, D.; Shaw, R. J.; Navas, P.; Puigserver, P.; Ingram, D. K.; De Cabo, R.; Sinclair, D. A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444, 337-342.
23. Barger, J. L.; Kayo, T.; Vann, J. M.; Arias, E. B.; Wang, J.; Hacker, T. A.; Wang, Y.; Raederstorff, D.; Morrow, J. D.; Leeuwenburgh, C.; Allison, D. B.; Saupe, K. W.; Cartee, G. D.; Weindruch, R.; Prolla, T. A. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One, 2008, 3, e2264.
24. Konings, E.; Timmers, S.; Boekschoten, M. V.; Goossens, G. H.; Jocken, J. W.; Afman, L. A.; Müller, M.; Schrauwen, P.; Mariman, E. C.; Blaak, E. E. The effects of 30 days resveratrol supplementation on adipose tissue morphology and gene expression patterns in obese men. Int. J. Obes. (Lond), 2014, 38, 470-473.
25. Park, H. J.; Yang, J. Y.; Ambati, S.; Della-Fera, M. A.; Hausman, D. B.; Rayalam, S.; Baile, C. A. Combined effects of genistein, quercetin, and resveratrol in human and 3T3-L1 adipocytes. J. Med. Food, 2008, 11, 773-783.
26. Lasa, A.; Churruca, I.; Eseberri, I.; Andrés-Lacueva, C.; Portillo, M. P. Delipidating effect of resveratrol metabolites in 3T3-L adipocytes. Mol. Nutr. Food Res., 2012, 56, 1559-1568.
27. Movahed, A.; Nabipour, I.; Lieben Louis, X.; Thandapilly, S. J.; Yu, L.; Kalantarhormozi, M.; Rekabpour, S. J.; Netticadan, T. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid. Based Compl. Alternat. Med., 2013, 2013, 851267.
28. Bhatt, J. K.; Thomas, S.; Nanjan, M. J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res., 2012, 32, 537-541.
29. Knop, F. K.; Konings, E.; Timmers, S.; Schrauwen, P.; Holst, J. J.; Blaak, E. E. Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. Diabet. Med., 2013, 30, 1214-1218.
30. Dash, S.; Xiao, C.; Morgantini, C.; Szeto, L.; Lewis, G. F. Highdose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler. Thromb. Vasc. Biol., 2013, 33, 2895-901.
31. Poulsen, M. M.; Vestergaard, P. F.; Clasen, B. F.; Radko, Y.; Christensen, L. P.; Stødkilde-Jørgensen, H.; Møller, N.; Jessen, N.; Pedersen, S. B.; Jørgensen, J. O. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebocontrolled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes, 2013, 62, 1186-1195.
32. Yoshino, J.; Conte, C.; Fontana, L.; Mittendorfer, B.; Imai, S. I.; Schechtman, K. B.; Gu, C.; Kunz, I.; Fanelli, F. R.; Patterson, B. W.; Klein, S. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab., 2012, 16, 658-664.
33. Ghanim, H.; Sia, C. L.; Abuaysheh, S.; Korzeniewsk, I. K.; Patnaik, P.; Marumganti, A.; Chaudhuri, A.; Dandona, P. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J. Clin. Endocrinol. Metab., 2010, 95, E1-E8.
34. Liu, K.; Zhou, R.; Wang, B.; Mi, M. T. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am. J. Clin. Nutr., 2014, 99, 1510-1519.
35. Crandall, J. P.; Barzilai, N. Exploring the promise of resveratrol: where do we go from here? Diabetes, 2013, 62, 1022-1023.
36. Kang, W.; Hong, H. J.; Guan, J.; Kim, D. G.; Yang, E. J.; Koh, G.; Park, D.; Han, C. H.; Lee, Y. J.; Lee, D. H. Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents. Metabolism, 2012, 61, 424-433.
37. Fauconneau, B.; Waffo-Teguo, P.; Huguet, F.; Barrier, L.; Decendit, A.; Merillon, J. M. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sci., 1997, 61, 2103-2110.
38. Ristow, M.; Zarse, K.; Oberbach, A.; Klöting, N.; Birringer, M.; Kiehntopf, M.; Stumvoll, M.; Kahn, C. R.; Blüher, M. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc. Natl. Acad. Sci. USA, 2009, 106, 8665-8670.
39. Skrobuk, P.; Von Kraemer, S.; Semenova, M. M.; Zitting, A.; Koistinen, H. A. Acute exposure to resveratrol inhibits AMPK activity in human skeletal muscle cells. Diabetologia, 2012, 55, 3051-3060.
40. Um, J. H.; Park, S. J.; Kang, H.; Yang, S.; Foretz, M.; McBurney, M. W.; Kim, M. K.; Viollet, B.; Chung, J. H. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes, 2010, 59, 554-563.
41. Cottart, C.-H.; Nivet-Antoine, V.; Laguillier-Morizot, C.; Beaudeux, J.-L. Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res., 2010, 54, 7-16.
42. Brown, V. A.; Patel, K. R.; Viskaduraki, M.; Crowell, J. A.; Perloff, M.; Booth, T. D.; Vasilinin, G.; Sen, A.; Schinas, A. M.; Piccirilli, G.; Brown, K.; Steward, W. P.; Gescher, A.; Brenner, D. E. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res., 2010, 70, 9003-9011.
43. Bode, L. M.; Bunzel, D.; Huch, M.; Cho, G. S.; Ruhland, D.; Bunzel, M.; Bub, A.; Franz, C. M.; Kulling, S. E. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am. J. Clin. Nutr., 2013, 97, 295-309.
44. Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P.; Geny, B.; Laakso, M.; Puigserver, P.; Auwerx, J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 2006, 127, 1109-1122.
45. Do, G. M.; Jung, U. J.; Park, H. J.; Kwon, E. Y.; Jeon, S. M.; McGregor, R. A.; Choi, M. S. Resveratrol ameliorates diabetesrelated metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice. Mol. Nutr. Food Res., 2012, 56, 1282-1291.
46. Price, N. L.; Gomes, A. P.; Ling, A. J.; Duarte, F. V.; Martin-Montalvo, A.; North, B. J.; Agarwal, B.; Ye, L.; Ramadori, G.; Teodoro, J. S.; Hubbard, B. P.; Varela, A. T.; Davis, J. G.; Varamini, B.; Hafner, A.; Moaddel, R.; Rolo, A. P.; Coppari, R.; Palmeira, C. M.; De Cabo, R.; Baur, J. A.; Sinclair, D. A. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab., 2012, 15, 675-690.
47. Louis, X. L.; Thandapilly, S. J.; Mohan Kumar, S. K.; Yu, L.; Taylor, C. G.; Zahradka, P.; Netticadan, T. Treatment with low-dose resveratrol reverses cardiac impairment in obese prone but not in obese resistant rats. J. Nutr. Biochem., 2012, 23, 1163-1169.
48. Andrade, J. M.; Frade, A. C.; Guimarães, J. B.; Freitas, K. M.; Lopes, M. T.; Guimarães, A. L.; De Paula, A. M.; Coimbra, C. C.; Santos, S. H. Resveratrol increases brown adipose tissue thermogenesis markers by increasing SIRT1 and energy expenditure and decreasing fat accumulation in adipose tissue of mice fed a standard diet. Eur. J. Nutr., 2014. [Epub ahead of print].
49. Rivera, L.; Moron, R.; Zarzuelo, A.; Galisteo, M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem. Pharmacol. 2009, 77, 1053-1063.
50. Gómez-Zorita, S.; Fernández-Quintela, A.; Macarulla, M. T.; Aguirre, L.; Hijona, E.; Bujanda, L.; Milagro, F.; Martínez, J. A.; Portillo, M. P. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br. J. Nutr., 2012, 107, 202-210.
51. Cho, S. J.; Jung, U. J.; Choi, M. S. Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice. Br. J. Nutr., 2012, 108, 2166-2175.
52. Baile, C. A.; Yang, J. Y.; Rayalam, S.; Hartzell, D. L.; Lai, C. Y.; Andersen, C.; Della-Fera, M. A. Effect of resveratrol on fat mobilization. Ann. N. Y. Acad. Sci., 2011, 1215, 40-47.
53. Alberdi, G.; Rodríguez, V. M.; Miranda, J.; Macarulla, M. T.; Arias, N.; Andrés-Lacueva, C.; Portillo, M. P. Changes in white adipose tissue metabolism induced by resveratrol in rats. Nutr. Metab. (Lond), 2011, 8, 29.
54. Alberdi, G.; Macarulla, M. T.; Portillo, M. P.; Rodríguez, V. M. Resveratrol does not increase body fat loss induced by energy restriction. J. Physiol. Biochem., 2014, 70, 639-646.
55. Barger, J. L. An adipocentric perspective of resveratrol as a calorie restriction mimetic. Ann. N. Y. Acad. Sci., 2013, 1290, 122-129.
56. Narkar, V. A.; Downes, M.; Yu, R. T.; Embler, E.; Wang, Y. X.; Banayo, E.; Mihaylova, M. M.; Nelson, M. C.; Zou, Y.; Juguilon, H.; Kang, H.; Shaw, R. J.; Evans, R. M. AMPK and PPARdelta agonists are exercise mimetics. Cell, 2008, 134, 405-415.
57. Delmas, D.; Xiao, J. Natural polyphenols properties: chemopreventive and chemosensitizing activities. Anticancer Agents Med. Chem., 2012, 12, 835.
58. Mercader, J.; Iffiú-Soltesz, Z.; Brenachot, X.; Földi, A.; Dunkel, P.; Balogh, B.; Attané, C.; Valet, P.; Mátyus, P.; Carpéné, C. SSAO substrates exhibiting insulin-like effects in adipocytes as a promising treatment option for metabolic disorders. Future Med. Chem., 2010, 2, 1735-1749.
59. Gomez-Zorita, S.; Tréguer, K.; Mercader, J.; Carpéné, C. Resveratrol directly affects in vitro lipolysis and glucose transport in human fat cells. J. Physiol. Biochem., 2013, 69, 585-593.
60. Carpéné, C.; Bour, S.; Visentin, V.; Pellati, F.; Benvenuti, S.; Iglesias-Osma, M. C.; Garcia-Barrado, M. J.; Valet, P. Amine oxidase substrates for impaired glucose tolerance correction. J. Physiol. Biochem., 2005, 61, 405-419.
61. Carpéné, C.; Grès, S.; Rascalou, S. The amine oxidase inhibitor phenelzine limits lipogenesis in adipocytes without inhibiting insulin action on glucose uptake. J. Neural. Transm., 2013, 120, 997-1004.
62. Carpéné, C.; Gomez-Zorita, S.; Gupta, R.; Grès, S.; Rancoule, C.; Cadoudal, T.; Mercader, J.; Gomez, A.; Bertrand, C.; Iffiu-Soltész, Z. Combination of low dose of the anti-adipogenic agents resveratrol and phenelzine in drinking water is not sufficient to prevent obesity in very-high-fat diet-fed mice. Eur. J. Nutr., 2014. [Epub ahead of Print].
63. Floyd, Z. E.; Wang, Z. Q.; Kilroy, G.; Cefalu, W. T. Modulation of peroxisome proliferator-activated receptor gamma stability and transcriptional activity in adipocytes by resveratrol. Metabolism, 2008, 57, S32-S38.
64. Strobel, P.; Allard, C.; Perez-Acle, T.; Calderon, R.; Aldunate, R.; Leighton, F. Myricetin, quercetin and catechin-gallate inhibit glucose uptake in isolated rat adipocytes. Biochem. J., 2005, 386, 471-478.
65. Vlachodimitropoulou, E.; Sharp, P. A.; Naftalin, R. J. Quercetiniron chelates are transported via glucose transporters. Free Radic. Biol. Med., 2011, 50, 934-944.
66. Shisheva, A.; Shechter, Y. Quercetin selectively inhibits insulin receptor function in vitro and the bioresponses of insulin and insulinomimetic agents in rat adipocytes. Biochemistry, 1992, 31, 8059-8063.
67. Ahn, J.; Lee, H.; Kim, S.; Park, J.; Ha, T. The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways. Biochem. Biophys. Res. Commun., 2008, 373, 545-549.
68. Arias, N.; Macarulla, M. T.; Aguirre, L.; Martínez-Castaño, M. G.; Portillo, M. P. Quercetin can reduce insulin resistance without decreasing adipose tissue and skeletal muscle fat accumulation. Genes Nutr., 2014, 9, 361.
69. Stewart, L. K.; Wang, Z.; Ribnicky, D.; Soileau, J. L.; Cefalu, W. T.; Gettys, T. W. Failure of dietary quercetin to alter the temporal progression of insulin resistance among tissues of C57BL/6J mice during the development of diet-induced obesity. Diabetologia, 2009, 52, 514-523.
70. Fischer-Posovszky, P.; Kukulus, V.; Tews, D.; Unterkircher, T.; Debatin, K. M.; Fulda, S.; Wabitsch, M. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am. J. Clin. Nutr., 2010, 92, 5-15.
71. Fang, X. K.; Gao, J.; Zhu, D. N. Kaempferol and quercetin isolated from Euonymus alatus improve glucose uptake of 3T3-L1 cells without adipogenesis activity. Life Sci., 2008, 62, 615-622.
72. Szkudelska, K.; Nogowski, L.; Szkudelski, T. Resveratrol and genistein as adenosine triphosphate-depleting agents in fat cells. Metabolism, 2011, 60, 720-729.
73. Breen, D. M.; Sanli, T.; Giacca, A.; Tsiani, E. Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem. Biophys. Res. Commun., 2008, 374, 117-122.
74. Lee, E. S.; Uhm, K. O.; Lee, Y. M.; Han, M.; Lee, M.; Park, J. M.; Suh, P. G.; Park, S. H.; Kim, H. S. CAPE (caffeic acid phenethyl ester) stimulates glucose uptake through AMPK (AMP-activated protein kinase) activation in skeletal muscle cells. Biochem. Biophys. Res. Commun., 2007, 361, 854-858.
75. Minakawa, M.; Miura, Y.; Yagasaki, K. Piceatannol, a resveratrol derivative, promotes glucose uptake through glucose transporter 4 translocation to plasma membrane in L6 myocytes and suppresses blood glucose levels in type 2 diabetic model db/db mice. Biochem. Biophys. Res. Commun., 2012, 422, 469-475.
76. Chen, S.; Li, J.; Zhang, Z.; Li, W.; Sun, Y.; Zhang, Q.; Feng, X.; Zhu, W. Effects of resveratrol on the amelioration of insulin resistance in KKAy mice. Can. J. Physiol. Pharmacol., 2012, 90, 237-242.
77. Liu, Y. L.; Cawthorne, M. A.; Stock, M. J. Biphasic effects of the β-adrenoceptor agonist, BRL 37344, on glucose utilisation in rat isolated skeletal muscle. Br. J. Pharmacol., 1996, 117, 1355-1361.
78. Carpéné, C.; Chalaux, E.; Lizarbe, M.; Estrada, A.; Mora, C.; Palacin, M.; Zorzano, A.; Lafontan, M.; Testar, X. β3-adrenergic receptors are responsible for the adrenergic inhibition of insulinstimulated glucose transport in rat adipocytes. Biochem. J., 1993, 296, 99-105.
79. Rayalam, S.; Yang, J.-Y.; Ambati, S.; Della-Fera, M. A.; Baile, C. A. Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother. Res., 2008, 22, 1367-1371.
80. Chen, S.; Li, Z.; Li, W.; Shan, Z.; Zhu, W. Resveratrol inhibits cell differentiation in 3T3-L1 adipocytes via activation of AMPK. Can. J. Physiol. Pharmacol., 2011, 89, 793-799.
81. Kang, N. E.; Ha, A. W.; Kim, J. Y.; Kim, W. K. Resveratrol inhibits the protein expression of transcription factors related adipocyte differentiation and the activity of matrix metalloproteinase in mouse fibroblast 3T3-L1 preadipocytes. Nutr. Res. Pract., 2012, 6, 499-504.
82. Kwon, J. Y.; Seo, S. G.; Heo, Y. S.; Yue, S.; Cheng, J. X.; Lee, K. W.; Kim, K. H. Piceatannol, natural polyphenolic stilbene, inhibits adipogenesis via modulation of mitotic clonal expansion and insulin receptor-dependent insulin signaling in early phase of differentiation. J. Biol. Chem., 2012, 287, 11566-11578.
83. Kim, S. H.; Park, H. S.; M. S., L.; Cho, Y.; Kim, Y. S.; Hwang, J. T.; Sung, M. J.; Kim, M. S.; Kwon, D. Y. Vitisin A inhibits adipocyte differentiation through cell cycle arrest in 3T3-L1 cells. Biochem. Biophys. Res. Commun., 2008, 372, 108-113.
84. Chiche, F.; Le Guillou, M.; Chetrite, G.; Lasnier, F.; Dugail, I.; Carpéné, C.; Moldes, M.; Fève, B. The antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes. Mol. Pharmacol., 2009, 75, 1052-1061.
85. Lee, H.; Lee, Y. J.; Choi, H.; Ko, E. H.; Kim, J. W. Reactive oxygen species facilitate adipocyte differentiation by accelerating mitotic clonal expansion. J. Biol. Chem., 2009, 284, 10601-10609.
86. Juman, S.; Yasui, N.; Okuda, H.; Ueda, A.; Negishi, H.; Miki, T.; Ikeda, K. Caffeic acid phenethyl ester suppresses the production of adipocytokines, leptin, tumor necrosis factor-alpha and resistin, during differentiation to adipocytes in 3T3-L1 cells. Biol. Pharm. Bull., 2011, 34, 490-494.
87. Szkudelska, K.; Nogowski, L.; Szkudelski, T. Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and antilipolytic action of insulin in isolated rat adipocytes. J. Steroid Biochem. Mol. Biol., 2009, 113, 17-24.
88. Pandey, P. R.; Okuda, H.; Watabe, M.; Pai, S. K.; Liu, W.; Kobayashi, A.; Xing, F.; Fukuda, K.; Hirota, S.; Sugai, T.; Wakabayashi, G.; Koeda, K.; Kashiwaba, M.; Suzuki, K.; Chiba, T.; Endo, M.; Fujioka, T.; Tanji, S.; Mo, Y. Y.; Cao, D.; Wilber, A. C.; Watabe, K. Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res. Treat., 2011, 130, 387-398.
89. Mercader, J.; Palou, A.; Bonet, M. L. Resveratrol enhances fatty acid oxidation capacity and reduces resistin and Retinol-Binding Protein 4 expression in white adipocytes. J. Nutr. Biochem., 2011, 22, 828-834.
90. Lasa, A.; Schweiger, M.; Kotzbeck, P.; Churruca, I.; Simón, E.; Zechner, R.; Del Puy Portillo, M. Resveratrol regulates lipolysis via adipose triglyceride lipase. J. Nutr. Biochem., 2012, 23, 379-384.
91. Kuppusamy, U. R.; Das, N. P. Potentiation of beta-adrenoceptor agonist-mediated lipolysis by quercetin and fisetin in isolated rat adipocytes. Biochem. Pharmacol., 1994, 47, 521-529.
92. Szkudelska, K.; Nogowski, L.; Szkudelski, T. The inhibitory effect of resveratrol on leptin secretion from rat adipocytes. Eur. J. Clin. Invest., 2009, 39, 899-905.
93. Olholm, J.; Paulsen, S. K.; Cullberg, K. B.; Richelsen, B.; Pedersen, S. B. Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. Int. J. Obes. (Lond), 2010, 34, 1546-1553.
94. Costa, C. S.; Rohden, F.; Hammes, T. O.; Margis, R.; Bortolotto, J. W.; Padoin, A. V.; Mottin, C. C.; Guaragna, R. M. Resveratrol upregulated SIRT1, FOXO1, and adiponectin and downregulated PPARβ1-3 mRNA expression in human visceral adipocytes. Obes. Surg., 2011, 21, 356-361.
95. Wang, A.; Liu, M.; Liu, X.; Dong, L. Q.; Glickman, R. D.; Slaga, T. J.; Zhou, Z.; Liu, F. Up-regulation of adiponectin by resveratrol: the essential roles of the Akt/FOXO1 and AMP-activated protein kinase signaling pathways and DsbA-L. J. Biol. Chem., 2011, 286, 60-66.
96. Chuang, C. C.; Martinez, K.; Xie, G.; Kennedy, A.; Bumrungpert, A.; Overman, A.; Jia, W.; McIntosh, M. K. Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor alpha-mediated inflammation and insulin resistance in primary human adipocytes. Am. J. Clin. Nutr., 2010, 92, 1511-1521.
97. Eseberri, I.; Lasa, A.; Churruca, I.; Portillo, M. P. Resveratrol metabolites modify adipokine expression and secretion in 3T3-L1 pre-adipocytes and mature adipocytes. PLoS One, 2013, 8, e63918.
98. Szkudelski, T.; Szkudelska, K. Anti-diabetic effects of resveratrol. Ann. N. Y. Acad. Sci., 2011, 1215, 34-39.
99. Dao, T. M.; Waget, A.; Klopp, P.; Serino, M.; Vachoux, C.; Pechere, L.; Drucker, D. J.; Champion, S.; Barthélemy, S.; Barra, Y.; Burcelin, R.; Sérée, E. Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PLoS One, 2011, 6, e20700.
100. Wong, Y. T.; Gruber, J.; Jenner, A. M.; Ng, M. P.; Ruan, R.; Tay, F. E. Elevation of oxidative-damage biomarkers during aging in F2 hybrid mice: protection by chronic oral intake of resveratrol. Free Radic. Biol. Med., 2009, 46, 799-809.
101. De Santi, C.; Pietrabissa, A.; Mosca, F.; Pacifici, G. M. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica, 2000, 30, 1047-1054.
102. Johnson, J. J.; Nihal, M.; Siddiqui, I. A.; Scarlett, C. O.; Bailey, H. H.; Mukhtar, H.; Ahmad, N. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol. Nutr. Food Res., 2011, 55, 1169-1176.
103. Yang, J. Y.; Della-Fera, M. A.; Rayalam, S.; Ambati, S.; Hartzell, D. L.; Park, H. J.; Baile, C. A. Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci., 2008, 82, 1032-1039.
104. Rayalam, S.; Della-Fera, M. A.; Yang, J. Y.; Park, H. J.; Ambati, S.; Baile, C. A. Resveratrol potentiates genistein's antiadipogenic and proapoptotic effects in 3T3-L1 adipocytes. J. Nutrition, 2007, 137, 2668-2673.
105. Bruckbauer, A.; Zemel, M. B.; Thorpe, T.; Akula, M. R.; Stuckey, A. C.; Osborne, D.; Martin, E. B.; Kennel, S.; Wall, J. S. Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr. Metab. (Lond.), 2012, 9, 77.
106. Bruckbauer, A.; Zemel, M. B. Synergistic effects of polyphenols and methylxanthines with leucine on AMPK/sirtuin-mediated metabolism in muscle cells and adipocytes. PLoS One, 2014, 9, e89166.
107. Most, J.; Goossens, G. H.; Jocken, J. W.; Blaak, E. E. Short-term supplementation with a specific combination of dietary polyphenols increases energy expenditure and alters substrate metabolism in overweight subjects. Int. J. Obes. (Lond.), 2014, 38, 698-706.
108. Arias, N.; Macarulla, M. T.; Aguirre, L.; Martínez-Castaño, M. G.; Gómez-Zorita, S.; Miranda, J.; Martínez, J. A.; Portillo, M. P. The combination of resveratrol and conjugated linoleic acid is not useful in preventing obesity. J. Physiol. Biochem., 2011, 67, 471-477.
109. Arias, N.; Miranda, J.; Macarulla, M. T.; Aguirre, L.; Fernandez-Quintela, A.; Andres-Lacueva, C.; Urpi-Sarda, M.; Portillo, M. P. The combination of resveratrol and conjugated linoleic acid attenuates the individual effects of these molecules on triacylglycerol metabolism in adipose tissue. Eur. J. Nutr., 2014, 53, 575-582.
110. Lasa, A.; Miranda, J.; Churruca, I.; Simón, E.; Arias, N.; Milagro, F.; Martínez, J. A.; Portillo, M. P. The combination of resveratrol and CLA does not increase the delipidating effect of each molecule in 3T3-L1 adipocytes. Nutr. Hosp., 2011, 26, 997-1003.
111. Kennedy, A.; Overman, A.; Lapoint, K.; Hopkins, R.; West, T.; Chuang, C. C.; Martinez, K.; Bell, D.; McIntosh, M. Conjugated linoleic acid-mediated inflammation and insulin resistance in human adipocytes are attenuated by resveratrol. J. Lipid Res., 2009, 50, 225-232.
112. Herranz-López, M.; Fernández-Arroyo, S.; Pérez-Sanchez, A.; Barrajón-Catalán, E.; Beltrán-Debón, R.; Menéndez, J. A.; Alonso-Villaverde, C.; Segura-Carretero, A.; Joven, J.; Micol, V. Synergism of plant-derived polyphenols in adipogenesis: perspectives and implications. Phytomedicine, 2012, 19, 253-261.
113. Kapetanovic, I. M.; Muzzio, M.; Huang, Z.; Thompson, T. N.; McCormick, D. L. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother. Pharmacol., 2011, 68, 593-601.
114. Lin, H. S.; Yue, B. D.; Ho, P. C. Determination of pterostilbene in rat plasma by a simple HPLCβUV method and its application in preclinical pharmacokinetic study. Biomed. Chromatography, 2009, 23, 1308-1315.
115. Grover, J. K.; Vats, V.; Yadav, S. S. Pterocarpus marsupium extract (Vijayasar) prevented the alteration in metabolic patterns induced in the normal rat by feeding an adequate diet containing fructose as sole carbohydrate. Diabetes Obes. Metab., 2005, 7, 414-420.
116. Satheesh, M. A.; Pari, L. The antioxidant role of pterostilbene in streptozotocin nicotinamide induced type 2 diabetes mellitus in Wistar rats. J. Pharm. Pharmacol., 2006, 58, 1483-1490.
117. Hsu, C. L.; Lin, Y. J.; Ho, C. T.; Yen, G. C. Inhibitory effects of garcinol and pterostilbene on cell proliferation and adipogenesis in 3T3-L1 cells. Food Funct., 2012, 3, 49-57.
118. Hsieh, T. C.; Bennett, D. J.; Lee, Y. S.; Wu, E.; Wu, J. M. In silico and biochemical analyses identify quinone reductase 2 as a target of piceatannol. Curr. Med. Chem. 2013, 20, 4195-4202.
119. Piotrowska, H.; Kucinska, M.; Murias, M. Biological activity of piceatannol: leaving the shadow of resveratrol. Mutat. Res., 2012, 750, 60-82.
120. He, S.; Yan, X. From resveratrol to its derivatives: new sources of natural antioxidant. Curr. Med. Chem., 2013, 20, 1005-1017.